6,791 Shares in Zimmer Biomet Holdings, Inc. $ZBH Bought by North Dakota State Investment Board

North Dakota State Investment Board bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 6,791 shares of the medical equipment provider’s stock, valued at approximately $611,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZBH. Brighton Jones LLC acquired a new stake in Zimmer Biomet during the 4th quarter worth about $204,000. Sivia Capital Partners LLC acquired a new stake in Zimmer Biomet during the 2nd quarter worth about $232,000. United Bank lifted its position in Zimmer Biomet by 10.7% during the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after acquiring an additional 1,153 shares during the period. Federated Hermes Inc. lifted its position in Zimmer Biomet by 129.2% during the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock worth $194,000 after acquiring an additional 1,202 shares during the period. Finally, Cerity Partners LLC lifted its position in Zimmer Biomet by 93.6% during the 2nd quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock worth $7,004,000 after acquiring an additional 37,116 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $85.39 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29. The business has a 50-day moving average price of $88.99 and a 200 day moving average price of $91.02. The firm has a market cap of $16.52 billion, a PE ratio of 22.18, a P/E/G ratio of 1.98 and a beta of 0.48.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. During the same quarter in the previous year, the business earned $1.81 EPS. Zimmer Biomet’s revenue for the quarter was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.47 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Investors of record on Tuesday, March 31st were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date was Tuesday, March 31st. Zimmer Biomet’s payout ratio is currently 24.94%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the transaction, the senior vice president owned 10,224 shares in the company, valued at $967,803.84. The trade was a 20.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.28% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ZBH has been the subject of several analyst reports. UBS Group reissued a “sell” rating and issued a $89.00 price objective on shares of Zimmer Biomet in a report on Wednesday, February 11th. TD Cowen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Monday, January 26th. Citizens Jmp decreased their price objective on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a report on Wednesday, April 29th. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, JPMorgan Chase & Co. decreased their price objective on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average price target of $102.80.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.